GLAND PHARMA Financial Statement Analysis
|
||
|
The Revenues of GLAND PHARMA have increased by 27.08% YoY .
The Earnings Per Share (EPS) of GLAND PHARMA has decreased by -35.70 % YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
GLAND PHARMA Last 5 Annual Financial Results
[BOM: 543245|NSE : GLAND]
| Consolidated | Mar2023 | Mar2022 | Mar2021 | Mar2020 |
|---|---|---|---|---|
| Revenues | ₹4,401 Cr | ₹3,463 Cr | ₹2,633 Cr | ₹2,633 Cr |
| Expenses | ₹2,891 Cr | ₹2,161 Cr | ₹1,678 Cr | ₹1,678 Cr |
| Operating Profit (Excl OI) | ₹1,510 Cr | ₹1,302 Cr | ₹955 Cr | ₹955 Cr |
| Other Income | ₹224 Cr | ₹135 Cr | ₹139 Cr | ₹139 Cr |
| Interest | ₹5.24 Cr | ₹3.41 Cr | ₹7.18 Cr | ₹7.18 Cr |
| Depreciation | ₹110 Cr | ₹99 Cr | ₹95 Cr | ₹95 Cr |
| Profit Before Tax | ₹1,619 Cr | ₹1,335 Cr | ₹993 Cr | ₹993 Cr |
| Profit After Tax | ₹1,212 Cr | ₹997 Cr | ₹773 Cr | ₹773 Cr |
| Consolidated Net Profit | ₹1,212 Cr | ₹997 Cr | ₹773 Cr | ₹773 Cr |
| Earnings Per Share (Rs) | ₹47.42 | ₹73.75 | ₹60.94 | ₹49.88 |
| PAT Margin (%) | 22.16 | 27.53 | 28.79 | 29.35 |
| ROE(%) | 10.34 | 18.61 | 20.97 | 21.29 |
| ROCE(%) | 14.04 | 24.85 | 28.00 | 27.39 |
| Total Debt/Equity(x) | 0.00 | 0.00 | 0.00 | 0.00 |
Key Financials |
||
| Market Cap | : | ₹ 28,343.2 Cr |
| Revenue (TTM) | : | ₹ 4,912.3 Cr |
| Net Profit(TTM) | : | ₹ 658.7 Cr |
| EPS (TTM) | : | ₹ 40.0 |
| P/E (TTM) | : | 43.0 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| GLAND PHARMA | -1% | -6.6% | 25.2% |
| SUN PHARMACEUTICAL INDUSTRIES | -0.1% | -6.3% | 53.5% |
| CIPLA | 1% | -5% | 53.3% |
| DR REDDYS LABORATORIES | 1.1% | 2.2% | 26% |
| ZYDUS LIFESCIENCES | 3.9% | -1.7% | 85.2% |
| DIVIS LABORATORIES | 3.2% | 15.3% | 23.6% |
| MANKIND PHARMA | -2.7% | 1.6% | NA |
| TORRENT PHARMACEUTICALS | -0.7% | 2.8% | 61.9% |
| LUPIN | 3.3% | 1.9% | 137.2% |
GLAND PHARMA Revenues
[BOM: 543245|NSE : GLAND]
| Y-o-Y | 27.08 % |
| 5 Yr CAGR | 18.67 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2023 | ₹4,401 Cr | 27.08 | |
| Mar2022 | ₹3,463 Cr | 31.51 | |
| Mar2021 | ₹2,633 Cr | 0.00 | |
| Mar2020 | ₹2,633 Cr | - | |
GLAND PHARMA Operating Profit
[BOM: 543245|NSE : GLAND]
| Y-o-Y | 15.97 % |
| 5 Yr CAGR | 16.48 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2023 | ₹1,510 Cr | 15.97 | |
| Mar2022 | ₹1,302 Cr | 36.29 | |
| Mar2021 | ₹955 Cr | 0.00 | |
| Mar2020 | ₹955 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | -8.75 % |
| 5 Yr CAGR | -1.83 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2023 | 34.32% | -8.75 | |
| Mar2022 | 37.61% | 3.67 | |
| Mar2021 | 36.28% | 0.00 | |
| Mar2020 | 36.28% | - | |
GLAND PHARMA Profit After Tax
[BOM: 543245|NSE : GLAND]
| Y-o-Y | 21.54 % |
| 5 Yr CAGR | 16.17 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2023 | ₹1,212 Cr | 21.54 | |
| Mar2022 | ₹997 Cr | 29.00 | |
| Mar2021 | ₹773 Cr | 0.00 | |
| Mar2020 | ₹773 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | -19.51 % |
| 5 Yr CAGR | -8.94 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2023 | 22.16 % | -19.51 | |
| Mar2022 | 27.53 % | -4.38 | |
| Mar2021 | 28.79 % | -1.91 | |
| Mar2020 | 29.35 % | - | |
GLAND PHARMA Earnings Per Share (EPS)
[BOM: 543245|NSE : GLAND]
| Y-o-Y | -35.70 % |
| 5 Yr CAGR | -1.67 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2023 | ₹47 | -35.70 | |
| Mar2022 | ₹74 | 21.02 | |
| Mar2021 | ₹61 | 22.17 | |
| Mar2020 | ₹50 | - | |
GLAND PHARMA Return on Capital Employed (ROCE)
[BOM: 543245|NSE : GLAND]
| Y-o-Y | -43.50 % |
| 5 Yr CAGR | -19.97 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2023 | 14.04% | -43.50 | |
| Mar2022 | 24.85% | -11.25 | |
| Mar2021 | 28% | 2.23 | |
| Mar2020 | 27.39% | - | |
GLAND PHARMA Share Price vs Sensex
| Current Share Price | : | ₹1,720.9 |
| Current MarketCap | : | ₹ 28,343.2 Cr |
| Updated EOD on | : | May 02,2024 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GLAND PHARMA | -1% |
-6.6% |
25.2% |
| SENSEX | 1% |
2.2% |
23.7% |
GLAND PHARMA related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| S&P BSE MID CAP | 3.8% | 8.8% | 69.8% |
| S&P BSE 150 MIDCAP | 3.3% | 8.3% | 62% |
| S&P BSE 400 MIDSMALLCAP | 2.7% | 9% | 63% |
| S&P BSE MIDSMALLCAP | 2.5% | 9.6% | 68.1% |
| S&P BSE QUALITY | 2.3% | 4.2% | 48.9% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY PHARMA | 2.9% | 1.9% | 53.5% |
| NIFTY FREE MIDCAP 100 | 2.3% | 6.9% | 63.7% |
| NIFTY MIDCAP150 | 2.2% | 7.3% | 61.6% |
| NIFTY MNC | 2% | 6.4% | 39.6% |
| NIFTY MID SMALL400 | 2% | 8.6% | 64.9% |
You may also like the below Video Courses
FAQ about GLAND PHARMA Financials
How the annual revenues of GLAND PHARMA have changed ?
The Revenues of GLAND PHARMA have increased by 27.08% YoY .
How the Earnings per Share (EPS) of GLAND PHARMA have changed?
The Earnings Per Share (EPS) of GLAND PHARMA has decreased by -35.70 % YoY .
Check out Intrinsic Value of Peers of GLAND PHARMA
Compare Stock Analytics of Peers of GLAND PHARMA
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
